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Amyloidosis in Patients
Referred for Transcatheter
Aortic Valve ReplacementAortic stenosis (AS) is the most common valve
disease in the developed world. Symptomatic severe
AS has poor outcomes unless treated. Transcatheter
aortic valve replacement (TAVR) numbers are growing
fast. Amyloidosis is caused by the deposition of
abnormally folded protein resulting in progressive
organ dysfunction. Wild-type transthyretin amyloid
(wtATTR) affects the heart, causing a restrictive
cardiomyopathy—deposits can be found in up to 25%of
individuals >85 years of age at autopsy (1,2). Until
recently, diagnosis required endomyocardial biopsy.
However, bone scintigraphy (99mTc-3,3-diphosphono-
1,2-propanodicarboxylic acid [DPD], 99mTc-pyrophos-
phate [PYP], or 99mTc-hydroxymethylene diphospho-
nate [HMDP]) is remarkably sensitive at detecting
cardiac transthyretin amyloid (ATTR) (1). This has led
to the development of formalized guidelines, enabling
noninvasive diagnosis (1). Castaño et al. (3) recently
reported occult cardiac ATTR in 16% of patients
post-TAVR.We investigated the coexistence of cardiac
ATTR in patients with severe AS before undergoing
TAVR.
We conducted a pre-specified futility interim
analysis of the ATTRact-AS study (NCT03029026),
which seeks the prevalence and impact of occult
cardiac amyloid in the elderly (aged 75 years and over)
with severe AS. The bone tracer was DPD. Scans were
graded using planar and single-photon emission
tomography/computed tomography images (Figure 1)
by 2 experienced observers and reviewed by
the National Amyloidosis Centre (NAC), United
Kingdom. If positive (Perugini grades 1 to 3), primary
light chain (AL) amyloidosis was excluded by blood
and urine monoclonal immunoglobulin testing. As per
protocol, clinicians were informed pre-TAVR only if
there was a possibility of AL amyloidosis. After TAVR,
all DPD-positive patients were referred to the NAC.
We recruited 101 patients (mean age 86  5 years,
43% male) who underwent DPD scintigraphy betweenOctober 2016 and August 2017, representing a quarter
of patients on the Barts Heart Centre TAVR pathway.
Echocardiographic baseline findings were: aortic
valve: peak velocity 4.19  0.68 m/s, peak gradient
7223mmHg,meangradient4315mmHg,meanarea
by continuity equation 0.71  0.22 cm2, mean area
indexed to body surface area (BSA) 0.40  011 cm2/m2;
left ventricle: mean ejection fraction 54  11%, mean
stroke volume indexed to BSA 38  10 ml/m2, mean
septal thickness 13  2 mm (range 7 to 21 mm).
Cardiac ATTR was diagnosed in 14 patients (13.9%,
95% confidence interval: 8% to 22%). Perugini grade
was 1 (n ¼ 4) and 2 (n ¼ 10). In this subgroup, 50%
were male, with a mean age of 88  6 years. The mean
aortic valve gradient and stroke volume indexed to
BSA were slightly lower in the DPD-positive cohort
(37  12 mm Hg vs. 44  15 mm Hg, and 32  7 ml/m2
vs. 38  11 ml/m2); however, this did not reach
statistical significance (p ¼ 0.11 for both).
Three DPD-positive patients had a plasma cell
dyscrasia, but after review at the NAC, AL amyloidosis
was felt unlikely in all cases. All DPD-positive
patients genotyped so far were wild type (n ¼ 5).
There was 1 periprocedural permanent pacemaker,
1 implantable cardiac defibrillator, and 1 spinal cord
infarction in the DPD-positive cohort. There were also
2 deaths pre-TAVR in the DPD-positive cohort (14%).
These findings support the work of Castaño et al.
(3) that approximately 1 in 7 patients currently
undergoing TAVR have occult cardiac amyloidosis—a
higher prevalence than surgical aortic valve replace-
ment cohorts (4). We note that 2 DPD-positive
patients died before TAVR, raising the possibility
that these patients represent a higher-risk subgroup
even pre-procedure. Furthermore, wtATTR typically
affects males more, but here the male and female
prevalence of amyloid were similar (16% prevalence
in men, 12% in women), as found in the heart failure
with preserved ejection fraction population (5).
Finally, the amyloid burden was skewed: rather than
a pyramidal distribution with DPD grade 1>2>3, DPD
grade 2 was dominant. This may support proposals of
an interaction between AS and amyloid.
The confirmation of such a high prevalence of
occult amyloid in TAVR patients has implications.
Cardiac amyloid profoundly alters the myocardium
and is likely to affect clinical presentation and
FIGURE 1 Cardiac Amyloid in Aortic Stenosis
An 88-year-old woman with severe aortic stenosis. (A) DPD scintigraphy fused single-photon emission tomography/computed tomography
illustrating cardiac tracer retention suggestive of cardiac amyloid, with large bilateral pleural effusions. (B) Fluoroscopy demonstrating the
26-mm Edwards Sapien 3 valve (Edwards Lifesciences, Irvine, California) in situ during the transcatheter aortic valve replacement. Note the
pre-existing dual-chamber pacemaker leads.
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464outcomes (procedural approaches, benefits, mortal-
ity). The importance of ongoing studies is high.Paul R. Scully, MBBS
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Therapy for End-Stage
Hypertrophic CardiomyopathyThe Need for Disease-Specific CriteriaCardiac resynchronization therapy (CRT) is a well-
established treatment for patients with heart failure
(HF) with reduced left ventricular ejection fraction
(LVEF), whereas its role in patients with preserved
LVEF is controversial at best (1). Hypertrophic car-
diomyopathy (HCM) is characterized by normal or
enhanced LVEF, even in patients with severe
